CapitalCell first biotech crowdequity platform in Europe
CapitalCell, is the investment crowdfunding platform dedicated to Health and Biotechnology was founded in 2014 in Barcelona by experts from other crowdfunding platforms with the aim of contributing to innovation in the Spanish biotechnology sector.
Capital Cell is the first crowdequity platform in Europe and the second worldwide that has already closed three projects since it started its activity in companies. Iproteos, Zeclinics and Immune Tolerance, the three projects have won a total amount of €100,000.
At present, the company SM Genomicshas launched a €150,000 crowdfunding round on Capitall Cell to finance the introduction in the Spanish amateur sports market of its Injury Genetic Report (IGL), a test to assess an athlete's predisposition to suffer non-contact muscle, ligament and tendon injuries, and to estimate the severity and recovery time.
"In addition to the crowdequity campaign, the company will also run a capital increase 300,000, reserved for business angels and venture capital companies" says Diego Gutierrez of Abra-Invest.
Precipita, the Spanish start-up for public biotech crowdfunding
The Spanish Foundation for Science and Technology (FECYT) launched in 2014 Precipitates, a project defined as a "meeting point for researchers and people interested in science" which has already funded 14 projects.
The projects that appear on the platform must have previously passed a public call for proposals. Each project has 90 days to reach the minimum target that each research has set, the maximum amount that can be obtained is €25,000.
An example of a company that has raised €20,000 thanks to the platform is Brainful Legends, a cognitive stimulation video game, aimed at learning competences and skills, both specific and general, for people with disabilities.
If you are looking for financing, please contact us. ABRA-INVEST, has a team of experts in alternative financing for biotechnology. Phone +34 946424142
Other posts that may interest you
EN 
ES